Quick Answer
Fortress Biotech, Inc. reported Net Income Loss of $6.82 million for the year ending 2025.
- Fortress Biotech, Inc. showed an increase of +114.8% in Net Income Loss from 2024 to 2025.
- This data is from Fortress Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2007 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$8.86 million | Q2 2013: -$10.67 million | Q3 2013: -$7.83 million | Q4 2013: -$9.80 million | Q1 2014: -$7.37 million | Q2 2014: -$4.71 million | Q3 2014: -$4.59 million | Q4 2014: -$3.71 million | Q1 2015: -$12.06 million | Q2 2015: -$6.18 million | Q3 2015: -$18.16 million | Q4 2015: -$12.04 million | Q1 2016: -$12.21 million | Q2 2016: -$12.48 million | Q3 2016: -$12.98 million | Q4 2016: -$17.43 million | Q1 2017: -$11.98 million | Q2 2017: -$17.37 million | Q3 2017: -$27.12 million | Q4 2017: -$10.41 million | Q1 2018: -$21.02 million | Q2 2018: -$21.61 million | Q3 2018: -$16.64 million | Q4 2018: -$24.88 million | Q1 2019: $1.39 million | Q2 2019: -$13.10 million | Q3 2019: -$12.76 million | Q1 2020: -$12.37 million | Q2 2020: -$13.31 million | Q3 2020: -$15.55 million | Q1 2021: -$8.82 million | Q2 2021: -$3.54 million | Q3 2021: -$20.78 million | Q1 2022: -$15.76 million | Q2 2022: -$21.36 million | Q3 2022: -$22.51 million | Q1 2023: -$21.54 million | Q2 2023: -$24.78 million | Q3 2023: -$5.05 million | Q1 2024: -$15.42 million | Q2 2024: -$10.95 million | Q3 2024: -$12.87 million | Q1 2025: -$10.58 million | Q2 2025: $15.49 million | Q3 2025: $5.85 million.
- Over the full 19 years of available data (2007 to 2025), Fortress Biotech, Inc.'s Net Income Loss has grown by 357.8%.
- Historical annual values: Fiscal year 2025: $6.82 million | Fiscal year 2024: -$46.00 million | Fiscal year 2023: -$60.64 million | Fiscal year 2022: -$86.58 million | Fiscal year 2021: -$64.70 million | Fiscal year 2020: -$46.53 million | Fiscal year 2019: -$39.96 million | Fiscal year 2018: -$84.15 million | Fiscal year 2017: -$66.88 million | Fiscal year 2016: -$55.10 million | Fiscal year 2015: -$48.43 million | Fiscal year 2014: -$20.39 million | Fiscal year 2013: -$37.16 million | Fiscal year 2012: -$27.61 million | Fiscal year 2011: -$36.36 million | Fiscal year 2010: -$9.98 million | Fiscal year 2009: -$3.67 million | Fiscal year 2008: -$3.80 million | Fiscal year 2007: -$2.64 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: